These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 16918890

  • 1. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):851-8. PubMed ID: 16918890
    [Abstract] [Full Text] [Related]

  • 2. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ.
    Eur J Gastroenterol Hepatol; 2009 Jan 01; 21(1):71-5. PubMed ID: 19060632
    [Abstract] [Full Text] [Related]

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 01; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 4. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D.
    Colorectal Dis; 2005 Mar 01; 7(2):164-8. PubMed ID: 15720356
    [Abstract] [Full Text] [Related]

  • 5. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 01; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 01; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 7. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.
    Gastroenterology; 2003 Apr 01; 124(4):917-24. PubMed ID: 12671888
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
    Bermejo F, López San Román A, Algaba A, van Domselaar M, Carneros JA, Rivero M, Piqueras B, Valer MP.
    Gastroenterol Hepatol; 2008 Dec 01; 31(10):629-32. PubMed ID: 19174078
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A.
    Tunis Med; 2009 Sep 01; 87(9):579-82. PubMed ID: 20180377
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
    Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA.
    Am J Gastroenterol; 2000 Dec 01; 95(12):3490-7. PubMed ID: 11151882
    [Abstract] [Full Text] [Related]

  • 11. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 01; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 12. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
    Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, Emmons J, Martinez A, Kelly KJ, Binion DG.
    Am J Gastroenterol; 2002 Jun 01; 97(6):1408-14. PubMed ID: 12094858
    [Abstract] [Full Text] [Related]

  • 13. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS.
    Aliment Pharmacol Ther; 2008 Jul 01; 28(2):221-7. PubMed ID: 18485127
    [Abstract] [Full Text] [Related]

  • 14. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 01; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 15. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.
    Aliment Pharmacol Ther; 2005 Dec 01; 22(11-12):1107-13. PubMed ID: 16305724
    [Abstract] [Full Text] [Related]

  • 16. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M, Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives.
    Gastroenterology; 2012 Jan 01; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [Abstract] [Full Text] [Related]

  • 17. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
    Gisbert JP, Panés J.
    Am J Gastroenterol; 2009 Mar 01; 104(3):760-7. PubMed ID: 19174781
    [Abstract] [Full Text] [Related]

  • 18. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS, Huo D.
    Gastroenterology; 2007 Mar 01; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract] [Full Text] [Related]

  • 19. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb 01; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 20. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
    Domènech E, Zabana Y, Mañosa M, Garcia-Planella E, Cabré E, Gassull MA.
    J Clin Gastroenterol; 2010 Jan 01; 44(1):34-7. PubMed ID: 19417683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.